Silver Tsunami is coming to healthcare: Time to prepare

Healthcare IT News | March 15, 2019

The Silver Tsunami is already rolling in and projections from the U.S. Census Bureau point to 2030 as a milestone year in which older people will actually outnumber children for the first time in history. Census Bureau data also estimates that one in every five Americans will be retirement age by that year. And beyond that, come 2035 some 78 million people will be over 65, while 76.7 million will be 18 or younger. That means it’s imperative for healthcare organizations, from solo practitioners to big practices, hospitals, health systems and insurance companies to start preparing now for what will inevitably be a transformative demographic shift. And that, in turn, is why HIMSS Media information brands Healthcare IT News, MobiHealthNews, Healthcare Finance News and HIMSS TV are conducting a Focus on Aging & The Silver Tsunami in this package.

Spotlight

Millions of people suffer brain injuries every year, many from car accidents. The worst can lead to permanent brain damage or even death. But many, like Paula, fight back and rebuild their lives.


Other News
HEALTH TECHNOLOGY

UPS to Acquire Multinational Healthcare Logistics Provider Bomi Group

UPS | August 08, 2022

UPS announced plans to acquire Bomi Group, an industry-leading multinational healthcare logistics provider. The transaction will add temperature-controlled facilities in 14 countries and nearly 3,000 highly-skilled Bomi Group team members to the UPS Healthcare network in Europe and Latin America. “As a leading global healthcare logistics company, Bomi enhances our portfolio of services and accelerates our journey to become the number one provider of complex healthcare logistics. UPS Healthcare and Bomi Group employees share similar values and our cultures are firmly rooted in a relentless focus on quality. The combination of our two teams will significantly improve our healthcare customers’ ability to continue to develop and deliver life-saving innovations.” EVP and President of UPS International, Healthcare and Supply Chain Solutions Kate Gutmann Since 1985, Bomi Group has provided high value-added services for the Medtech and Pharma sectors with a customized and tailored approach. It is a quality-focused company devoted to healthcare that has built solid and long-lasting business relationships with more than 150 multinational customers worldwide. Key Bomi Group leaders, including CEO Marco Ruini, will continue in their roles to provide seamless service to Bomi Group customers after the transaction closes. Bomi Group’s employees will also continue to play vital roles in the combined organization. “With over 35 years in the healthcare logistics industry, our team has developed best-in-class services designed to meet and exceed the needs of our medical technology and pharmaceutical customers,” said Ruini. “Joining the UPS team will expand those capabilities and create an even more integrated and powerful global network for our customers.” The acquisition will add more than 350 temperature-controlled vehicles and four million square feet to the UPS Healthcare global footprint, offering customers access to faster shipping times, greater production flexibility, and offerings to help them attract new business. The acquisition will play a key role in the delivery of next-generation pharmaceutical and biologic treatments that increasingly require time-critical and temperature-sensitive logistics. “We are focused on building healthcare logistics capabilities and services that allow our customers to deliver the newest healthcare innovations,” said UPS Healthcare President Wes Wheeler. “We are excited to combine Bomi’s talent, expertise and capabilities with UPS Healthcare – together, we will provide unmatched solutions to our customers, powered by UPS’s integrated, global smart logistics network.” The acquisition of Bomi is part of UPS Healthcare’s continued expansion of its network and services to meet growing demand – including Bomi, UPS Healthcare has doubled its global footprint since 2020. Recent expansions include newly constructed and soon-to-be-opened dedicated state-of-the-art healthcare logistics facilities in Germany and Australia, and expanded campuses in Hungary and the Netherlands. UPS Healthcare also recently enhanced UPS Premier, a technology-led service that can prioritize and track critical shipments within 10 feet of their location anywhere in UPS’s global network. UPS Premier brings worldwide visibility, control, reliability and product recovery capabilities to UPS Healthcare customers. These expansions and new services meet the complex and varied needs of UPS Healthcare’s customers, helping them turn logistics into a competitive advantage. The transaction is expected to close by the end of the year, subject to customary regulatory review and approval. The value and terms of the transaction are not being disclosed at this time. J.P. Morgan Securities LLC served as the financial advisor to UPS. About UPS UPS is one of the world’s largest companies, with 2021 revenue of $97.3 billion, and provides a broad range of integrated logistics solutions for customers in more than 220 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s more than 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. UPS also takes an unwavering stance in support of diversity, equity and inclusion. About UPS Healthcare UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 11+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS® Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. About Bomi Group BOMI GROUP is a leading Italian multinational company in the field of integrated logistics serving the Healthcare sector. Bomi is the logistics partner of more than 150 customers worldwide, including major players in the medical device, in vitro diagnostics, biomedical and pharmaceutical sectors. The Group is present through its subsidiaries and affiliates in 14 countries worldwide, with a particular focus on Europe and South America, employs over 3,000 people and has its own fleet of vehicles for daily deliveries to hospitals, clinics, laboratories, pharmacies and home patients.

Read More

HEALTH TECHNOLOGY

Murata Vios Announces Integration with PointClickCare’s EHR Platform

Murata Vios, Inc | June 24, 2022

Murata Vios, Inc., developer of the Vios Monitoring System, is proud to announce the launch of its integration with PointClickCare, the leading cloud‐based software vendor for the senior care market. The integration will allow healthcare facilities to seamlessly integrate vital signs data into residents’ electronic health records for clinical review, helping to eliminate data entry time lags, transcription errors, and improve clinician efficiency. “Real‐time understanding of a resident’s vital signs can help prevent hospital readmissions because care teams can more quickly identify and treat the early signs of clinical deterioration. With the Vios Monitoring System and its Remote Monitoring Services, PointClickCare customers have a better way to capture this data and respond to changes in a resident’s condition. It can also free up clinical time that was previously spent on manually spot‐checking and recording vital signs every few hours.” Amit Patel, CEO of Murata Vios The Vios Monitoring System is a wireless, FDA‐cleared patient monitoring platform designed to improve resident safety and outcomes. The system delivers insights and value to post‐acute care providers by Continuously monitoring vital signs. The Vios Monitoring System measures high‐fidelity 7‐lead ECG, heart rate, oxygen levels, pulse rate, respiratory rate, and posture data. Improving 24/7/365 oversight of changes in resident conditions. With Vios Remote Monitoring Services, a team of cardiac‐trained technicians can alert the on‐site care team to any changes in a resident’s condition, enabling them to quickly respond to resident deterioration that could lead to readmission. Identifying risk of pressure injuries. The Vios Chest Sensor has a built‐in 3‐axis accelerometer that detects and displays the resident’s posture in real‐time. When turn orders are added, the system can determine when a patient is at‐risk of developing a pressure injury so the on‐site care team can address the issue. Additional information regarding the integration can be found on the PointClickCare Marketplace – an online platform that enables customers to easily evaluate authorized third-party technology partners. Partners listed on the PointClickCare Marketplace offer integrated apps and/or services that are designed to be quickly deployed and work seamlessly with providers’ existing workflows. “The PointClickCare Marketplace offers the widest range of integrated solutions available to the market,” says Chris Beekman, Marketplace Director, PointClickCare. “Our partnership with Murata Vios is further testament to our continually growing partner network and ecosystem, and the wealth of possibilities it provides our customers to extend their technology capabilities.” About Murata Vios, Inc. Murata Vios, Inc., a subsidiary of Murata Manufacturing Co., Ltd., developed the Vios Monitoring System (VMS) to improve patient outcomes and reduce costs across the care continuum. Healthcare facilities can use the wireless, FDA‐cleared vital signs monitoring solution on existing IT infrastructure and instantly deploy the VMS to meet the acuity needs of patients across various care settings. Vios Remote Monitoring Services support healthcare teams with real‐time patient event analysis and notifications, helping to maximize patient safety while minimizing the burden on stretched clinical staff. About PointClickCare PointClickCare is a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights at any stage of a patient’s healthcare journey. PointClickCare’s single platform spans the care continuum, fostering proactive, holistic decision‐making and improved outcomes for all. Over 22,000 long‐term post‐acute care providers, and 1,600 hospitals use PointClickCare today, enabling care collaboration and value‐based care delivery for millions of lives across North America.

Read More

FUTURE OF HEALTHCARE

Azenta Announces Agreement to Acquire B Medical Systems

Azenta, Inc. | August 09, 2022

Azenta, Inc. announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410 million. Additional cash consideration, up to €50 million, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in October 2022. B Medical is headquartered in Hosingen, Luxembourg and is one of the leading vaccine cold chain providers serving primarily fast-growing emerging markets, which require secure and reliable temperature-controlled storage and transport solutions. The portfolio includes vaccine transport systems with real-time monitoring solutions, medical refrigeration for ambient to -86°C temperatures, and blood management solutions. B Medical has an installed base of more than 500,000 units spanning approximately 150 countries across the globe. The Luxembourg headquarters includes a state-of-the-art, highly automated manufacturing facility. This acquisition complements Azenta's cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens. "We are excited to add B Medical into our growing portfolio of offerings. B Medical has done an outstanding job carving out a strong market position in the vaccine cold chain, and we see a breadth of opportunities to drive even further value from the portfolio by leveraging the Azenta platform." Steve Schwartz, President and CEO of Azenta B Medical CEO, Luc Provost, who has been with the company for over 20 years, and Jesal Doshi, Deputy CEO since 2015, are expected to join Azenta and continue to lead the business. Mr. Provost commented, "We are excited to join the Azenta team as we combine our capabilities and expertise in cold chain solutions to drive the next leg of growth. Together, I look forward to continuing our mission to create technology that helps save lives across the world." B Medical generated approximately €109 million in revenue over the past twelve months ending June 30, 2022. Management expects the acquisition to be accretive to non-GAAP earnings in fiscal year 2023 and accretive to GAAP earnings in fiscal year 2024. About B Medical Systems B Medical is a global manufacturer and distributor of cold chain solutions. Based in Hosingen, Luxembourg, the company was founded in 1979, when the World Health Organization (WHO) approached Electrolux to provide a solution to safely store and transport vaccines around the world. The three major business portfolios include Vaccine Cold Chain, Medical Refrigeration, and Blood Management solutions. Notable products include vaccine transport systems (ice-lined and solar direct drive) with remote temperature monitoring devices, laboratory refrigerators, ultra-low freezers, contact-shock freezers, and transport solutions. B Medical Systems' products are used in approximately 150 countries and have an installed base of more than half a million products across the world. About Azenta Life Sciences Azenta, Inc. is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc.from Brooks Automation, Inc.

Read More

HEALTH TECHNOLOGY

HeartBeam Expands Patient Population for Emergency Department Software Technology Solution

HeartBeam, Inc. | July 04, 2022

HeartBeam, Inc. a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, announced that HeartBeam is expanding the available patient population for the Company’s Emergency Department software technology solution. In evaluating the ECG database for the clinical validation of HeartBeam’s platform technology, a significant portion of consecutive patients fell into the category of unstable angina, a serious cardiac condition. In light of the most recent 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain and in consultation with its clinical advisors, HeartBeam elected to include the full data set for clinical validation studying in support of the 510K submission. The expanded scope of the clinical validation study will provide access to a broader patient population for HeartBeam’s technology once cleared by the FDA. Due to the expanded available patient population, HeartBeam expects to file a 510K with the full data set for clinical validation no later than August 15, 2022 and does not affect the timeline for 510K submission of the Telehealth product. “It is important to include unstable angina as a diagnosis for analysis. Patients with unstable angina may have subtle electrical changes brought on by ischemia without definitive injury to the cardiac tissue. Given HeartBeam’s advanced technology solution, there is potential to identify patients who cannot be diagnosed by traditional ECG capabilities but may require intervention.” Russell Jones, MD, Interventional Cardiologist, Chair of the Ischemia Performance Improvement Committee at Phoebe Putney Health System HeartBeam’s platform technology is anticipated to assist physicians in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen. Chest pain is the second most common reason for an emergency department visit, with high costs associated with these visits. HeartBeam’s software solution may offer more accurate heart attack detection to triage patients and expedite treatment. The HeartBeam technology platform has not yet been evaluated by the FDA and is not approved for clinical use in the USA or other global geographies. “We believe our commercialization path is on track,” said Branislav Vajdic, PhD, CEO and founder. “The decision to include the broader patient population does not impact the scheduled submission for HeartBeam’s core technology platform for our Telehealth solution, which remains on schedule to submit in Q4 2022.” About HeartBeam, Inc. HeartBeam, Inc. is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack.

Read More